Previous close | 9.45 |
Open | 9.55 |
Bid | 9.23 x 100 |
Ask | 9.32 x 400 |
Day's range | 9.22 - 9.86 |
52-week range | 5.93 - 21.17 |
Volume | |
Avg. volume | 938,948 |
Market cap | 740.118M |
Beta (5Y monthly) | 0.86 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.09 |
Earnings date | 07 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 27.43 |
CAMBRIDGE, Mass., July 23, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its second quarter 2024 financial results and provide a business update on Thursday, August 8, 2024, at 8:15am ET.
CAMBRIDGE, Mass., July 12, 2024--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards on July 10, 2024, covering an aggregate of 285,000 shares of its common stock to two newly hired employees, consisting of inducement stock
We recently compiled a list of the 10 Most Shorted Stocks That Are Loved by Analysts. In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against the other shorted stocks that are loved by analysts. Short selling is one of the more controversial ways of making […]